Cargando…

Granulocyte-macrophage colony-stimulating factor alone or with dacarbazine in metastatic melanoma: a randomized phase II trial

The potential antitumoural effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) led us to evaluate GM-CSF alone or with dacarbazine (DTIC) in metastatic melanoma in first line randomized phase II. Treatment was arm A: GM-CSF: 5 μg kg(−1), bid, 14 consecutive days every 21 days and arm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ravaud, A, Delaunay, M, Chevreau, C, Coulon, V, Debled, M, Bret-Dibat, C, Courbon, F, Gualde, N, Bui, B Nguyen
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2001
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363949/ https://www.ncbi.nlm.nih.gov/pubmed/11720430 http://dx.doi.org/10.1054/bjoc.2001.2120

Ejemplares similares

Relative Efficacy of Granulocyte-Macrophage Colony-Stimulating Factor, Dacarbazine, and Glycoprotein 100 in Metastatic Melanoma: An Indirect Treatment Comparison
por: Quinn, Casey, et al.
Publicado: (2016)

A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma
por: Middleton, M R, et al.
Publicado: (2000)

Dacarbazine Combined Targeted Therapy versus Dacarbazine Alone in Patients with Malignant Melanoma: A Meta-Analysis
por: Jiang, Guan, et al.
Publicado: (2014)

Meta-Analysis of the Safety and Efficacy of Interferon Combined With Dacarbazine Versus Dacarbazine Alone in Cutaneous Malignant Melanoma
por: Xin, Yong, et al.
Publicado: (2016)

Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin.
por: Pectasides, D., et al.
Publicado: (1989)

Granulocyte, granulocyte–macrophage, and macrophage colony-stimulating factors can stimulate the invasive capacity of human lung cancer cells
por: Pei, X-H, et al.
Publicado: (1999)

Toxicity and feasibility of adjuvant high-dose interferon alpha-2b in patients with melanoma in clinical oncologic practice
por: Ravaud, A, et al.
Publicado: (1999)

Dacarbazine and interferon α with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)
por: Hauschild, A, et al.
Publicado: (2001)

Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma
por: Algazi, A P, et al.
Publicado: (2012)

Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine
por: Propper, D J, et al.
Publicado: (2000)

Targeted Therapies Compared to Dacarbazine for Treatment of BRAF(V600E) Metastatic Melanoma: A Cost-Effectiveness Analysis
por: Shih, Vanessa, et al.
Publicado: (2015)

Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma
por: Kaufman, Howard L, et al.
Publicado: (2014)

Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies
por: Eisen, T, et al.
Publicado: (2011)

Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma
por: Daponte, Antonio, et al.
Publicado: (2013)

Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine
por: Nocera, M, et al.
Publicado: (2000)

Dacarbazine nanoparticle topical delivery system for the treatment of melanoma
por: Hafeez, Abdul, et al.
Publicado: (2017)

A randomised, phase II study of intetumumab, an anti-α(v)-integrin mAb, alone and with dacarbazine in stage IV melanoma
por: O'Day, S, et al.
Publicado: (2011)

Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma
por: Sherrill, B, et al.
Publicado: (2013)

A patient with metastatic melanoma presenting with gastrointestinal perforation after dacarbazine infusion: a case report
por: Oosting, Sjoukje F, et al.
Publicado: (2010)

Granulocyte colony-stimulating factor (G-CSF) transiently suppresses mitogen-stimulated T-cell proliferative response
por: Reyes, E, et al.
Publicado: (1999)

Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma
por: Scheithauer, W, et al.
Publicado: (1999)

A phase I trial of repeated tumour-infiltrating lymphocyte (TIL) infusion in metastatic melanoma.
por: Ravaud, A., et al.
Publicado: (1995)

Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma
por: Hoeller, Christoph, et al.
Publicado: (2016)

Effect of intraperitoneally administered recombinant murine granulocyte-macrophage colony-stimulating factor (rmGM-CSF) on the cytotoxic potential of murine peritoneal cells
por: Klimp, A H, et al.
Publicado: (1999)

Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma
por: Long, Georgina V, et al.
Publicado: (2015)

Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study.
por: Punt, C. J., et al.
Publicado: (1997)

Dacarbazine (DTIC)-based chemotherapy or chemoimmunotherapy of patients with disseminated malignant melanoma.
por: Mulder, N. H., et al.
Publicado: (1994)

Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma.
por: Lee, S. M., et al.
Publicado: (1993)

Synergistic inhibitory effects of the oxyresveratrol and dacarbazine combination against melanoma cells
por: Lee, Sang Gyu, et al.
Publicado: (2021)

Dacarbazine-Loaded Targeted Polymeric Nanoparticles for Enhancing Malignant Melanoma Therapy
por: Xiong, Wei, et al.
Publicado: (2022)

Immunostimulation using granulocyte- and granulocyte-macrophage colony stimulating factor in patients with severe sepsis and septic shock
por: Schefold, Joerg C
Publicado: (2011)

Effects of Interleukin‐6 and Granulocyte Colony‐stimulating Factor on the Proliferation of Leukemic Blast Progenitors from Acute Myeloblastic Leukemia Patients
por: Suzuki, Toshiya, et al.
Publicado: (1990)

Prospective Study of the Evolution of Blood Lymphoid Immune Parameters during Dacarbazine Chemotherapy in Metastatic and Locally Advanced Melanoma Patients
por: Mignot, Grégoire, et al.
Publicado: (2014)

Sequential Combination Chemotherapy of Dacarbazine (DTIC) with Carboplatin and Paclitaxel for Patients with Metastatic Mucosal Melanoma of Nasal Cavity and Paranasal Sinuses
por: Omata, W., et al.
Publicado: (2017)

Co-Delivery of Eugenol and Dacarbazine by Hyaluronic Acid-Coated Liposomes for Targeted Inhibition of Survivin in Treatment of Resistant Metastatic Melanoma
por: Mishra, Harshita, et al.
Publicado: (2019)

Critical analysis of an oncolytic herpesvirus encoding granulocyte-macrophage colony stimulating factor for the treatment of malignant melanoma
por: Hughes, Tasha, et al.
Publicado: (2014)

Phase I–II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma
por: Plummer, R, et al.
Publicado: (2013)

Thrombin Stimulates Synthesis of Macrophage Colony-Stimulating Factor, Granulocyte-Macrophage Colony-Stimulating Factor and Granulocyte Colony-Stimulating Factor by Human Proximal Tubular Epithelial Cells in Culture
por: Shimaya, Yuko, et al.
Publicado: (2012)

Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma
por: Yamazaki, N., et al.
Publicado: (2015)

Baseline platelet counts and derived inflammatory biomarkers: prognostic relevance in metastatic melanoma patients receiving Endostar plus dacarbazine and cisplatin
por: Yang, Lingge, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_bke69qa99lj6tak6ilgmk86813